Vincere Biosciences is dedicated to conquering age-related diseases through the development of small molecule therapeutics empowered by a suite of computational tools alongside traditional biology and drug discovery expertise.
Our innovative approach focuses on developing small molecules that enhance the removal of damaged mitochondria by modulating mitochondrial quality control mechanisms, such as mitophagy. With the potential to be groundbreaking, these small molecules could become the world's first-ever medicines capable of slowing down or even halting the progression of debilitating conditions like Parkinson's disease and other age-related diseases. By doing so, we aim to transform the lives of hundreds of millions of patients across the globe.
We welcome you to follow our page for more content about our company, our dedicated team, and the science that drives what we do.
Company Details
- Employees
- 10
- Founded
- -
- Address
- 245 Main Street,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- vincerebio.com
- Keywords
- Beiersdorf.
- HQ
- Cambridge, Massachusetts
Vincere Biosciences Questions
Vincere Biosciences's website is vincerebio.com
Vincere Biosciences's LinkedIn profile is https://www.linkedin.com/company/vincere-bio
Vincere Biosciences has
10 employees.
View email and phone details for 10
employees at Vincere Biosciences.
Vincere Biosciences's industry is
Biotechnology Research
Vincere Biosciences's top competitors are
Beiersdorf,
Truebinding,
Mitochem Therapeutics,
Kreamedica Inc.,
Neuroinitiative,
Cnd Life Sciences,
Tiziana Life Sciences,
Alamar Biosciences, Inc.,
Neuroage Therapeutics,
Longgame Ventures.
Vincere Biosciences's categories are Biotechnology Research
Vincere Biosciences's founding year is 2018
